ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0337

Characterization of Statin Induced Myopathy in the Hospital Setting

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0079

Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0197

Characterizing Diet and Neighborhood Resources in Patients with Systemic Lupus Erythematosus

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0517

Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0646

Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0606

Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events

SpA Including PsA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0154

Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0462

Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0327

Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0119

Clinical and Serological Distinctions and Evolutionary Predictors in Antiphospholipid Syndrome and Systemic Lupus Erythematosus: A Multicenter Cohort Analysis

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0647

Clinical Associations and Outcomes of Pericarditis in Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0147

Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0339

Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0754

Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0627

Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease

SLE – Diagnosis, Manifestations, & Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].